Cost-utility analysis of combination medical therapies in chronic coronary syndrome: a comparative study using real-world and patient-level data from Iran.

While revascularisation may improve outcomes for patients with ST-elevation myocardial infarction (STEMI) and multivessel CAD, recent meta-analyses suggest that there may not be significant differences in health outcomes for patients with CCS between MT therapy, PCI and CABG. 18 25 26 Previous economic studies have shown that MT is a cost-effective alternative to revascularisation for patients eligible for both treatments. 9 27 However, it is vital to consider revascularisation as a complementary strategy for patients with CCS. 28 As Fearon and colleagues discovered, PCI of coronary lesions with reduced fractional flow reserve leads to improved outcomes.

also in 2,774 other papers